Trial Profile
Rate of infections in patients with myelofibrosis treated with Ruxolitinib and conventional therapy: a retrospective,monocentric study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 22 Jul 2017 New trial record
- 25 Jun 2017 Results (n=22) of a cohort assessing rate of infections, presented at the 22nd Congress of the European Haematology Association.